Christelle Ansaldi

GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma <i>via</i> modulation of lysosomal functions

Sonia Brun, Eloïne Bestion, Éric Raymond et al. · Autophagy · 2021 · 75 citations · Full text

Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis

Pierre Nahon, Marie Najean, Richard Layese et al. · JHEP Reports · 2021 · 46 citations · Full text

Hepatology, Medical Imaging, Cancer Detection +13

GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma

Sonia Brun, Firas Bassissi, Cindy Serdjebi et al. · Investigational New Drugs · 2019 · 37 citations

Hepatology, Biliary Tract, Biliary Cancer +10

First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers

James J. Harding, Ahmad Awada, Gaël S. Roth et al. · Liver Cancer · 2022 · 26 citations · Full text

Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results

Philippe Halfon, Christelle Ansaldi, Guillaume Pénaranda et al. · PLoS ONE · 2021 · 16 citations · Full text